Search alternatives:
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
mm decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
mm decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
15421
-
15422
Dual Inhibition of Topoisomerase II and Tyrosine Kinases by the Novel Bis-Fluoroquinolone Chalcone-Like Derivative HMNE3 in Human Pancreatic Cancer Cells
Published 2016“…Consistent with cellular apoptosis data, a significant decrease in topoisomerase IIβ activity was noted following treatment with HMNE3 for 24 h. …”
-
15423
DRP2B is partially required for flg22-induced endocytosis of FLS2.
Published 2014“…Representative maximum-intensity projection images and zoomed insets of FLS2-GFP fluorescence are shown, with bright pixels corresponding to increased abundance of FLS2-GFP at a given location. Scale bars = 10 µm. (D) Quantification of FLS2-GFP in puncta at 0, 35–45 or 50–60 min after elicitation with 1 µM flg22 indicates that loss of <i>DRP2B</i> resulted in ∼20% decrease in flg22-stimulated endocytosis of FLS2-GFP (35–45 min, P = 0.0204; 50–60 min, P = 0.0396). …”
-
15424
Vascular nitrite concentrations at rest and following ischemia in control and diabetic subjects.
Published 2015“…<p>Blood draws were taken at rest and 60sec following release (hyperemia) of the five minute upper arm occlusion (50mmHg above SBP) before and following the ride. …”
-
15425
-
15426
-
15427
-
15428
-
15429
-
15430
-
15431
Mcl-1 degradation is slowed by a T163E mutation (but not T163A) in transfected CHO cells.
Published 2012“…In Panel B, the decline in Mcl-1 expression at 3 hours in 2 independent experiments ranged from 53–66% with WT-Mcl-1, 25–54% with Mcl-1-S162A, and 25–50% with Mcl-1-T163A. While the decline in expression with WT-Mcl-1 appeared be slightly greater than that seen with Mcl-1-T163A, this was not a consistent finding. …”
-
15432
-
15433
-
15434
Baseline characteristics.
Published 2025“…In addition, the CBT-I group reported a greater decrease in depressive (adjusted difference −1.0 [−1.6 to −0.5]; Cohen’s <i>d</i> = 0.53; <i>p</i> < 0.001) and insomnia symptoms (−2.0 [−2.7 to −1.3], <i>d</i> = 0.78; <i>p</i> < 0.001) than the controls at post-intervention and throughout 6-month follow-up. …”
-
15435
Secondary outcome results.
Published 2025“…In addition, the CBT-I group reported a greater decrease in depressive (adjusted difference −1.0 [−1.6 to −0.5]; Cohen’s <i>d</i> = 0.53; <i>p</i> < 0.001) and insomnia symptoms (−2.0 [−2.7 to −1.3], <i>d</i> = 0.78; <i>p</i> < 0.001) than the controls at post-intervention and throughout 6-month follow-up. …”
-
15436
-
15437
-
15438
-
15439
-
15440